Watch VKTX. Know when insiders buy.
One email the day a filing lands. Free.
VKTX
Viking Therapeutics, Inc.
29.94
−0.57 −1.87%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
51
WATCH · shorts 51
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5BP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$534.8MNET CASH —52W 26.29 – 42.13SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$132.6M | −$128M | — | -1.10 | −$125.2M | — | — | Jul 29 |
| Q1 2026 · Mar 31 | $0 | — | — | −$164.1M | −$158.3M | — | -1.37 | −$114M | — | — | Apr 30 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$164.7M | −$157.7M | — | -1.39 | −$85.3M | — | — | Feb 11 |
| Q3 2025 · Sep 30 | $0 | — | — | −$98.6M | −$90.8M | — | -0.81 | −$94M | — | — | Oct 23 |
| Q2 2025 · Jun 30 | $0 | — | — | −$74.6M | −$65.6M | — | -0.58 | −$47.1M | — | — | Jul 29 |
| Q1 2025 · Mar 31 | $0 | — | — | −$55.5M | −$45.6M | — | -0.41 | −$52.3M | — | — | Apr 30 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$46.2M | −$35.4M | — | -0.32 | −$31.2M | — | — | Feb 11 |
| Q3 2024 · Sep 30 | $0 | — | — | −$36.6M | −$24.9M | — | -0.22 | −$22M | — | — | Oct 23 |
| Q2 2024 · Jun 30 | $0 | — | — | −$34.1M | −$22.3M | — | -0.20 | −$28.5M | — | — | Jul 23 |
| Q1 2024 · Mar 31 | $0 | — | — | −$34.1M | −$27.4M | — | -0.26 | −$6.1M | — | — | Apr 24 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$29.3M | −$24.6M | — | -0.25 | −$17.6M | — | — | Feb 11 |
| Q3 2023 · Sep 30 | $0 | — | — | −$27.3M | −$22.5M | — | -0.23 | −$19.7M | — | — | Oct 23 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$393.3M | −$359.6M | — | -3.19 | −$278.7M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$150.9M | −$110M | — | -1.01 | −$87.8M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$100.8M | −$85.9M | — | -0.91 | −$73.4M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$70.4M | −$68.9M | — | -0.90 | −$48.4M | — | — | $6.8M | — |
| FY2021 · to Dec 31 | $0 | — | −$55.7M | −$55M | — | -0.71 | −$47.6M | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | −$42.7M | −$39.5M | — | -0.54 | −$21.8M | — | — | — | — |
Every number comes from Viking Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.